What is US 8,080,663 about (cevimeline)?
US 8,080,663 is a U.S. patent associated with cevimeline (a medication used for dry mouth in people with Sjögren’s syndrome). Patent number 8,080,663 is listed in patent databases under “cevimeline,” which indicates the patent is tied to intellectual property covering some aspect of the drug or its formulation/use. [1]
Who holds US 8,080,663, and what does it cover exactly?
Patent databases typically identify:
- the patent holder/assignee,
- the specific claims (what is legally protected),
- and the “link” between the patent and the drug product.
If you tell me the assignee name shown on your page (or paste the abstract/claims text you’re looking at), I can help translate what the claims mean in plain English and how that claim scope relates to cevimeline.
How does US 8,080,663 relate to generic or “cevimeline” market entry?
For drug patents, the usual practical question is whether the patent blocks generic competition until it expires or is invalidated. Patent databases often link a listed patent to a specific drug and strength/form, which can be used to assess whether a generic would face patent “stays” or litigation.
To do that accurately for US 8,080,663, I need the drug product details shown in the listing (for example, dosage form and strength), because patent listings can be product-specific.
When does US 8,080,663 expire?
Patent expiration depends on factors such as:
- the filing date and basic term,
- any regulatory extensions,
- and terminal disclaimers.
DrugPatentWatch.com is a common place to check the listed expiration and related exclusivity information for drug-linked patents. [1] If you share the expiration date shown there, I can explain what it means for market entry timing.
Can you share the DrugPatentWatch page for US 8,080,663?
Yes. Here is the relevant listing page for cevimeline and the patent number you mentioned: [1]
---
Sources
[1] https://www.drugpatentwatch.com/p/cevimeline/us8080663